This article is available to members only. Please enjoy the abstract for free. Subscribe for instant access to the full article.
This content is restricted to subscribers
Continue Reading...
Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.
Members enjoy free PDF downloads on all articles. Join today
Author Affiliations
Department of Internal Medicine, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Pharmacology Department, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina
Hospital de Emergencias Psiquiátricas Torcuato de Alvear, Buenos Aires, Argentina
Department of Internal Medicine, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Pharmacology Department, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina
Department of Internal Medicine, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Pharmacology Department, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina
Institute for Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
Department of Critical Care Medicine. Sunnybrook Health Sciences Centre, Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Ontario, Canada
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts
Corresponding author: Alejandro G. Szmulewicz, MD, MPH, Department of Epidemiology, Harvard T.H. Chan School of Public Health, 677 Huntington Ave, Boston, MA, 02115 ([email protected]).
References (35)
Buist AS, McBurnie MA, Vollmer WM, et al; BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007;370(9589):741–750. PubMedCrossRef
Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007;370(9589):765–773. PubMedCrossRef
Jones DR, Macias C, Barreira PJ, et al. Prevalence, severity, and co-occurrence of chronic physical health problems of persons with serious mental illness. Psychiatr Serv. 2004;55(11):1250–1257. PubMedCrossRef
Yohannes AM, Alexopoulos GS. Depression and anxiety in patients with COPD. Eur Respir Rev. 2014;23(133):345–349. PubMedCrossRef
Szmulewicz AG, Angriman F, Pedroso FE, et al. Long-term antipsychotic use and major cardiovascular events: a retrospective cohort study. J Clin Psychiatry. 2017;78(8):e905–e912. PubMedCrossRef
Ferraris A, Szmulewicz AG, Vazquez FJ, et al. Antipsychotic use among adult outpatients and venous thromboembolic disease: a retrospective cohort study. J Clin Psychopharmacol. 2017;37(4):405–411. PubMedCrossRef
Szmulewicz AG, Ferraris A, Rodriguez A, et al. All-cause mortality in older adults with affective disorders and dementia under treatment with antipsychotic drugs: a matched-cohort study. Psychiatry Res. 2018;265(265):82–86. PubMed
van Strien AM, Souverein PC, Keijsers CJPW, et al. Association between urinary tract infections and antipsychotic drug use in older adults. J Clin Psychopharmacol. 2018;38(4):296–301. PubMedCrossRef
Kuo CJ, Yang SY, Liao YT, et al. Second-generation antipsychotic medications and risk of pneumonia in schizophrenia. Schizophr Bull. 2013;39(3):648–657. PubMedCrossRef
Schneider-Thoma J, Efthimiou O, Bighelli I, et al. Second-generation antipsychotic drugs and short-term somatic serious adverse events: a systematic review and meta-analysis. Lancet Psychiatry. 2019;6(9):753–765. PubMedCrossRef
Zhang XY, Zhou DF, Cao LY, et al. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J Clin Psychiatry. 2004;65(7):940–947. PubMedCrossRef
de Witte L, Tomasik J, Schwarz E, et al. Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment. Schizophr Res. 2014;154(1-3):23–29. PubMedCrossRef
Chen ML, Wu S, Tsai TC, et al. Regulation of macrophage immune responses by antipsychotic drugs. Immunopharmacol Immunotoxicol. 2013;35(5):573–580. PubMedCrossRef
Wang MT, Tsai CL, Lin CW, et al. Association between antipsychotic agents and risk of acute respiratory failure in patients with chronic obstructive pulmonary disease. JAMA Psychiatry. 2017;74(3):252–260. PubMedCrossRef
Laursen TM, Munk-Olsen T, Agerbo E, et al. Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder. Arch Gen Psychiatry. 2009;66(7):713–720. PubMedCrossRef
Inghammar M, Engström G, Ljungberg B, et al. Increased incidence of invasive bacterial disease in chronic obstructive pulmonary disease compared to the general population: a population based cohort study. BMC Infect Dis. 2014;14(1):163. PubMedCrossRef
Khorrami F, Ahmadi M, Sheikhtaheri A. Evaluation of SNOMED CT content coverage: a systematic literature review. Stud Health Technol Inform. 2018;248:212–219. PubMed
von Elm E, Altman DG, Egger M, et al; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453–1457. PubMedCrossRef
Vijay A, Becker JE, Ross JS. Patterns and predictors of off-label prescription of psychiatric drugs. PLoS One. 2018;13(7):e0198363. PubMedCrossRef
Carnes M, Howell T, Rosenberg M, et al. Physicians vary in approaches to the clinical management of delirium. J Am Geriatr Soc. 2003;51(2):234–239. PubMedCrossRef
VanderWeele TJ. Principles of confounder selection. Eur J Epidemiol. 2019;34(3):211–219. PubMedCrossRef
Cole SR, Hernán MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008;168(6):656–664. PubMedCrossRef
Sattar N, Preiss D. Reverse causality in cardiovascular epidemiological research: more common than imagined? Circulation. 2017;135(24):2369–2372. PubMedCrossRef
Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509. CrossRef
VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167(4):268–274. PubMedCrossRef
Drzyzga L, Obuchowicz E, Marcinowska A, et al. Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav Immun. 2006;20(6):532–545. PubMedCrossRef
Basu S, Dasgupta PS. Dopamine, a neurotransmitter, influences the immune system. J Neuroimmunol. 2000;102(2):113–124. PubMedCrossRef
Steele TA, Brahmi Z. Chlorpromazine inhibits human natural killer cell activity and antibody-dependent cell-mediated cytotoxicity. Biochem Biophys Res Commun. 1988;155(2):597–602. PubMedCrossRef
Stapel B, Sieve I, Falk CS, et al. Second generation atypical antipsychotics olanzapine and aripiprazole reduce expression and secretion of inflammatory cytokines in human immune cells. J Psychiatr Res. 2018;105:95–102. PubMedCrossRef
Calverley PMA, Anderson JA, Celli B, et al; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–789. PubMedCrossRef
Govind R, Fonseca de Freitas D, Pritchard M, et al. Clozapine treatment and risk of COVID-19 infection: retrospective cohort study. Br J Psychiatry. 2020;1–7. PubMedCrossRef
Stoecker ZR, George WT, O’Brien JB, et al. Clozapine usage increases the incidence of pneumonia compared with risperidone and the general population: a retrospective comparison of clozapine, risperidone, and the general population in a single hospital over 25 months. Int Clin Psychopharmacol. 2017;32(3):155–160. PubMedCrossRef
Chang CK, Chen PH, Pan CH, et al. Antipsychotic medications and the progression of upper respiratory infection to pneumonia in patients with schizophrenia. Schizophr Res. 2020;222:327–334. PubMedCrossRef
Angriman F, Masse M-H, Adhikari NKJ. Defining standard of practice: pros and cons of the usual care arm. Curr Opin Crit Care. 2019;25(5):498–504. PubMedCrossRef
Huitfeldt A, Hernan MA, Kalager M, et al. Comparative effectiveness research using observational data: active comparators to emulate target trials with inactive comparators. EGEMS (Wash DC). 2016;4(1):1234. PubMed